Protocol Ledger

NCT04817332 · Phase III · COMPLETED

STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19

Interventional Phase III clinical trial protocol NCT04817332 sponsored by University of Dundee in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-06-05 Enrollment: 406 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04817332
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)406 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04817332
Protocol FieldVerified Registry Value
NCT IdentifierNCT04817332
Consolidated Lead SponsorUniversity of Dundee
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment406 participants (ACTUAL)
Registered Start Date2020-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04817332
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI